This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
Top line 48-wk results in Q4 2023.
CLINICAL TRIALS
MOMENTUM STUDY: Efficacy and Safety of Pemvidutide in the Treatment of Obesity
STATUS: Ongoing
For more informationIMPACT STUDY: Efficacy and Safety of Pemvidutide in Subjects with Nonalcoholic Steatohepatitis (NASH)
STATUS: Enrolling
For more informationThe purpose of the study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Topline data in Q1 2025.
Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)
STATUS: Ongoing
For more informationA study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive Chronic Hepatitis B (CHB).
Top line data readout H1 2024.
